FDA approves Journey Medical's drug for long-term skin condition-March 2024-www.financetom.com

FDA approves Journey Medical's drug for long-term skin condition

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA approves Journey Medical's drug for long-term skin condition

Nov 4, 2024 11:38 AM

Nov 4 (Reuters) - The U.S. Food and Drug Administration

has approved Journey Medical's ( DERM ) drug for the treatment

of a long-term skin condition called rosacea, the company said

on Monday.

Previous page： BRIEF-Telix To Acquire ARTMS Inc And Its Advanced Isotope Production Platform Next page： PRESS DIGEST- Financial Times - March 5

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Telix To Acquire ARTMS Inc And Its Advanced Isotope Production Platform

Mar 4, 2024

March 4 (Reuters) - Telix Pharmaceuticals Ltd ( TLPPF ): * TELIX TO ACQUIRE ARTMS, INC. AND ITS ADVANCED ISOTOPE PRODUCTION PLATFORM * TELIX PHARMACEUTICALS LTD ( TLPPF ) - ACQUISITION HAS POTENTIAL TO BE FINANCIALLY ACCRETIVE, ADD ADDITIONAL REVENUE * TELIX PHARMACEUTICALS LTD ( TLPPF ) - ACQUISITION HAS POTENTIAL TO HAVE POSITIVE IMPACT ON GROSS MARGINS FOR ILLUCCIX...

PRESS DIGEST- Financial Times - March 5

Mar 4, 2024

March 5 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Cinven agrees to buy majority stake in fund administrator Alter Domus - Jeremy Hunt set to give motorists 5 bln pound tax break in the Budget - 'Erroneous' filings highlight flaws...

Tandem Diabetes Care Plans $250 Million Private Placement Notes -- Shares Decline After Hours

Mar 4, 2024

05:31 PM EST, 03/04/2024 (MT Newswires) -- Tandem Diabetes Care ( TNDM ) said Monday it plans a private placement of $250 million in principal amount of convertible notes due 2029. Initial purchasers will have the option to buy up to an additional $37.5 million principal amount of notes, according to the company. Net proceeds, along with cash at hand,...

BRIEF-Bowflex Inc Says Co Files For Voluntary Chapter 11 Protection & Reaches Stalking Horse Agreement To Facilitate Sale

Mar 4, 2024

March 5 (Reuters) - BowFlex Inc ( BFX ): * BOWFLEX INC. ( BFX ) FILES FOR VOLUNTARY CHAPTER 11 PROTECTION AND REACHES STALKING HORSE AGREEMENT TO FACILITATE SALE * BOWFLEX ( BFX ) - SECURED COMMITMENT FOR $25 MILLION IN DIP FINANCING TO CONTINUE TO FULFILL CUSTOMER ORDERS AND SUPPORT ORDINARY COURSE OPERATIONS * BOWFLEX ( BFX ) :...